Jason R. Manro

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Rikke Holmgaard, David Schaer, Yanxia Li et al. · Journal for ImmunoTherapy of Cancer · 2018 · 369 citations · Full text

Life Sciences, Immunology, Oncology +17

Developmental Expression of the Major Human Hepatic CYP3A Enzymes

Jeffrey Stevens, Ronald N. Hines, Chungang Gu et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 364 citations

Life Sciences, Biochemistry, Developmental Biology +16

Developmental Expression of Human Hepatic CYP2C9 and CYP2C19

Sevasti B. Koukouritaki, Jason R. Manro, Sandra A. Marsh et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 322 citations

Medicine, Developmental Biology, Pharmacology +17

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan et al. · Oncotarget · 2017 · 173 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

S. Betty Yan, Victoria L. Peek, Rose T. Ajamie et al. · Investigational New Drugs · 2012 · 161 citations · Full text

Medicine, Oncology, Pharmacology +17